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Osteoarthritis is a degenerative disease associated with the degradation of cartilage. One 
of the few therapies aimed at regenerating cartilage, autologous chondrocyte implantation (ACI), 
involves ex vivo expansion and re-implantation of patient derived chondrocytes. Chondrocytes 
have relatively slow proliferation rates, however, and rapidly de-differentiate during the ex vivo 
culture performed with ACI. The objective of this study was to develop microcarriers (µCs) that 
provide a microenvironment that more closely mimics the complex extracellular matrix of native 
cartilage for chondrocyte expansion and retention of phenotype.   
Porcine cartilage was isolated, lyophilized, milled, and sifted overnight to obtain µCs 
approximately 450 µm and 600 µm in diameter. Multiple decellularization procedures were 
tested and ultimately a series of chemical and enzymatic washes resulted in removal of more 
than 98% of the original DNA content. Preliminary seeding experiments performed with 
chondrogenic ATDC5 cells resulted in chondrogenic proliferation and viability over 7 days of 
culture on decellularized cartilage microcarriers (DC µCs).   
Primary human chondrocytes were then cultured on the DC µCs, commercially available 
gelatin CultiSpher®-G (CG µCs), or tissue culture polystyrene over 14 days. Chondrocyte-laden 
DC µCs contained significantly more GAGs than the CG µCs or plated tissue culture polystyrene 
(TCPS) chondrocytes at all time points.  
Ongoing experiments are evaluating changes in chondrogenic phenotype on µCs through 
histological, immunohistochemical, and gene expression analysis. DC µCs support chondrocyte 
proliferation, and although the rate of expansion is slower than CG µCs or TCPS, these 
microcarriers have GAG/DNA ratios more similar to that of native cartilage. This makes DC µCs 




BACKGROUND & LITERATURE REVIEW 
CARTILAGE TISSUE: COMPOSITION AND MORPHOLOGY 
Articular hyaline cartilage tissue is a specialized connective tissue found in joints of the 
body. Articular cartilage functions as a smooth frictionless surface for articulation of mobile 
joints during movement and also distributes the weight of biomechanical forces. This tissue type 
is unique in that it is both avascular and aneural, lacking both blood vessels and nerves [1]. 
Cartilage tissue has limited healing capacity due to its avascular nature, and therefore faces 
difficulty healing after events in which it is heavily damaged [1]. For this reason, damage to 
cartilage and degenerative diseases involving cartilage are linked to musculoskeletal morbidity 
[1]. 
Given that cartilage lacks vasculature and neural networks, the primary importance of its 
composition is due to the specialized cells it is composed of, known as chondrocytes, and the 
dense extracellular matrix (ECM) which the chondrocytes produce and in which they reside [1]. 
Chondrocytes 
Chondrocytes are the primary cell type of articular cartilage tissue. They are sparsely 
distributed within the cartilage ECM, only making up 2% of the total volume of articular 
cartilage [1, 2]. Their functions involve the production, maintenance, and repair of the ECM. 
Chondrocytes maintain upkeep of the ECM by synthesizing various ECM components, including 
proteins and glycosaminoglycans (GAGs). As with most cells, chondrocyte phenotype and 
activity can be altered by their exposure or lack of exposure to certain biochemical and 
biomechanical factors. A meta-analysis demonstrated that multiple growth factors (members of 
the transforming growth factor-β superfamily, members of the fibroblast growth factor family, 
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insulin-like growth factor-1, and platelet-derived growth factor) are all potential targets as 
possible treatments to manage degenerative cartilage diseases such as arthritis due to growth 
factor influence on cartilage repair and chondrogenesis [3]. Most strategies are unable to 
recapitulate the complex milieu of growth factors involved in chondrocyte homeostasis.  
Extracellular Matrix 
ECM is the structure that surrounds and supports the chondrocytes within articular 
cartilage. ECM is majorly composed of tissue fluid, collagens, and proteoglycans. The majority 
of articular cartilage weight is made up of 65-80% tissue fluid, with the remaining 20-35% being 
mostly attributed to collagens and proteoglycans [1]. Molecules with a smaller presence in total 
ECM composition such as lipids, phospholipids, glycoproteins, and growth factors can also be 
found present in the ECM in trace amounts. One of the most prominent collagens in cartilage 
ECM is type II collagen (col II), making up 90 - 95% of the collagen in the ECM and providing 
major structural support in combination with proteoglycans [1]. Proteoglycans themselves 
account for 10-15% of articular cartilage in wet weight [1]. The most prevalent proteoglycan in 
cartilage is aggrecan. Within the cartilage tissue, aggrecan interacts with heavily sulfated 
glycosaminoglycan chains, which are covalently attached [1]. The sulfated glycosaminoglycan 
chains create a highly negative network that provides the ECM with osmotic properties which 
enable cartilage to resist compressive mechanical loading [1]. 
The continuous interactions between chondrocytes and cartilage ECM are what provide 
articular cartilage with the components necessary to promote a frictionless, load bearing 
connective tissue that is vital to the demanding biomechanical environment of diarthrodial joints. 
When this relationship is compromised, the damaging effects to the cartilage tissue as a whole 
propagate throughout the tissue, and cartilage’s limited capacity for intrinsic healing results in a 
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disease pathology that is not easily corrected without intervention. This in turn can lead to 
degenerative joint diseases that involve chronic pain, inflammation, and degradation as the 
disease progresses throughout the joint [1]. 
OSTEOARTHRITIS: PREVALENCE AND TREATMENTS 
Osteoarthritis 
Osteoarthritis (OA) is a degenerative disease associated with the degradation of hyaline 
articular cartilage and affects nearly 27 million people in the US [4].  OA affects 13.9% of 
American adults aged 25-65 and 33.6% of adults over 65, and is marked by the degradation of 
cartilage in major joints such as the knee and hip [4]. OA involves major changes in cartilage 
function, including adversely affecting the load-bearing, stabilizing, and lubricating functions of 
healthy articular cartilage [5]. As OA pathology propagates, a single compositional change in 
one aspect of the ECM can have detrimental effects in other compositional aspects of the ECM. 
For example, a decrease in proteoglycans increases the likelihood of contact stresses. In turn, 
weakening of the collagen network due to enhanced contact stresses reduces osmotic and 
electrostatic forces that functionally allow cartilage tissue to redistribute loads [5]. As OA 
progresses, certain metabolic activities of the ECM cease to function, and synthesis of important 
structural molecules such as aggrecan and collagen ceases. Not only does OA lead to phenotypic 
changes in cartilage ECM, but it also has been linked to inflammatory responses within the joint. 
Inflammation of the joint adds to degradation of the cartilage and in turn activates the pain 
commonly associated with arthritis of the joint [5]. 
Current gold standard – joint arthroplasty 
Common treatments for OA including pain relievers, anti-inflammatory drugs, cortisone 
shots, and lubrication injections are not regenerative and often necessitate total knee 
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replacement, 450,000 of which were performed annually in 2004 alone [6-8]. Although hip and 
knee replacement can improve quality of life, these major surgical procedures have multiple 
associated risks, and there is concern for long-term outcomes, especially in younger patients [9, 
10]. 
Alternative method – Autologous chondrocyte implantation 
An FDA approved cell therapy used to treat chondral defects but not OA involves a 
surgical procedure known as autologous chondrocyte implantation (ACI). ACI is one of the only 
methods used to regenerate cartilage [11]. In this procedure, a patient has a small sample of 
healthy hyaline cartilage resected from a non-weight bearing area of the affected joint [11]. The 
chondrocytes are then enzymatically isolated in a neutral buffer in preparation for expansion that 
usually takes 11-21 days [11]. The current procedure for chondrocyte expansion involves 
monolayer (2D) expansion in standard growth media and a polystyrene culture dish following 
typical cell culture procedures and enzymatic release of attached cells [11]. After expansion, 
these chondrocytes are transplanted into the defect area of the joint and secured using the 
periosteal flap [11]. Current drawbacks of ACI are the slow proliferation rates of isolated 
chondrocytes, as well as the tendency for chondrocytes to dedifferentiate during ex vivo 
expansion [12]. This dedifferentiation during ex vivo culture is a process by which the 
chondrocytes form a scar-like fibrocartilage instead of healthy hyaline cartilage [12]. The 
aforementioned dedifferentiation can be quantified by changes in collagen expression patterns, in 
which collagen II is downregulated and there is increased expression of collagen I [12]. This 
formation of fibrocartilage leads to calcification of the cartilage and promotes osteogenesis, 
which can lead to the growth of bone in vivo instead of replenishing the depleted hyaline 
cartilage, and results in additional pain and bone to bone contact in the affected joint [12]. Due to 
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these complications, the field investigating chondrocyte expansion and proliferation is pursuing 
solutions to address the current problems with ACI. In countries outside of the U.S., 
fibrocartilage formation is decreased by using matrix like materials in place of the periosteal flap 
to secure the transplanted chondrocytes in the defect in what is referred to as matrix-induced ACI 
(MACI) [13]. The current matrices approved for use are membranes derived from a porcine 
collagen I/III matrix [13]. Chondrocytes cultured in vitro on collagen I/III matrices produced 
more collagen II and GAGs in comparison to chondrocytes cultured on polystyrene, however, a 
separate study found high rates of apoptosis and lower cell proliferation on collagen I/III 
matrices when compared to collagen II matrices [13]. Collagen I and collagen III are less 
physiologically relevant collagens in articular cartilage, and there remains a gap in current MACI 
procedures to employ a cell delivery vehicle that better mimics the complex microenvironment 
found in vivo in healthy articular cartilage tissue. 
CARTILAGE TISSUE ENGINEERING PLATFORMS 
Decellularized cartilage 
Xenogeneic and allogeneic implants often elicit an inflammatory response due to cellular 
antigens found in the tissues [14]. Often, extracellular proteins are largely conserved among 
species and cellular components can be removed through decellularization through a series of 
chemical and/or enzymatic washes while preserving ECM from the native tissue [14]. 
Decellularized tissues have shown potential for applications in various tissue types including 
heart valves, various other vasculature, connective tissues including tendons, ligaments and 
muscles, and even entire specialized organs such as the liver and bladder [15-21]. Decellularized 
cartilage has been shown to contain a variety of bioactive molecules that are found in native 
articular cartilage including proteoglycans, collagen II, and multiple chondrogenic growth factors 
[22-26]. Several studies have investigated the effect of chondrocyte culture on decellularized 
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articular cartilage [22-25]. When compared to tissue culture treated polystyrene (TCPS) 
monolayer expansion, culture on sheets of decellularized cartilage provided a greater retention of 
chondrogenic phenotype and limited the dedifferentiation normally experienced ex vivo [22-25]. 
Using decellularized cartilage for cellular expansion was beneficial for phenotypic retention, and 
decellularized cartilage is also biodegradable, which provides tremendous cell delivery 
applications [14]. The current drawback of using decellularized cartilage sheets to deliver cells is 
the inability to achieve successful tissue integration and cellular infiltration during scaffold 
delivery to chondral defects, as found by an ovine study evaluating meniscal scaffolds in vivo 
[27]. 
Microcarrier Expansion 
Microcarriers are used as scalable culture platforms for a variety of cell lines. 
Microcarriers enhance proliferation when compared to monolayer culture due to their high 
surface area to volume ratio [28, 29]. In comparison to conventional monolayer culture, 
microcarrier culture supports improved cellular proliferation and yield with respect to time [30]. 
Manufactured microcarriers can be produced with many different materials, and chondrocyte 
expansion has been demonstrated on polystyrene microcarriers, glass microcarriers coated in 
polymer, and gelatin based microcarriers [30]. Though microcarriers outperform monolayer 
culture of chondrocytes in proliferation rate and efficiency, the synthetic microcarriers do not 
prevent dedifferentiation over extended culture periods [30]. Gelatin based microcarriers derived 
from multiple collagen types facilitated significant GAG production when compared to 
monolayer chondrogenic culture [30]. Cultured primary human chondrocytes on these gelatinous 
Cultispher-G microcarriers resulted in significantly higher glycosaminoglycan content than T-
flask cultured chondrocytes when the constructs were implanted subcutaneously in a mouse 
model after 14 days of in vitro culture on either microcarrier or monolayer platforms [30]. 
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Though microcarriers have been shown to aid in retention of chondrogenic phenotype compared 
to monolayer culture, over the culture period chondrocytes gradually decrease synthesis of 
articular cartilage ECM [31]. These gelatin microcarriers are composed primarily of denatured 
collagen I and do not provide the same physiological relevance as collagen type II, found in high 
concentrations of healthy articular cartilage ECM and lack the complex milieu of other proteins, 
GAGs, proteoglycans, and growth factors found in a healthy cartilage microenvironment [14, 
30]. Thus, there remains a need for a more physiologically relevant culture platform that 
maintains chondrogenic phenotype during expansion and supports cells with the appropriate 
microenvironment for direct implantation.  
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CHAPTER 2 
A NOVEL MICROCARRIER PLATFORM FOR CHONDROGENIC 
EXPANSION 
RATIONALE 
 Xenogeneic and even allogeneic tissue contains antigens that can trigger immune 
responses upon implantation, and regenerative therapies using native tissues should aim to 
reduce this potential inflammatory response. Decellularization is a technique that combines 
mechanical and chemical treatments to remove cellular contents from tissues, leaving an ECM 
containing growth factors, proteins, and structural morphologies found in the native tissue of the 
body [14]. These scaffolds are rich in bioactive factors and have been used previously for cell 
culture and phenotype retention, however, decellularized tissue sheets often do not result in 
successful tissue integration and cellular infiltration when used as a delivery mechanism in vivo. 
Microcarriers are a cell culture platform used in cell proliferation and expansion. Their surface 
area to volume ratio allows for culture of large amounts of cells with decreased requirements for 
space and nutrients. Microcarriers have also been used as delivery devices to deliver cells or 
compounds in vivo. Commercially available microcarriers are currently composed of single or 
dual molecules and do not recapitulate the complex microenvironment needed for chondrocytes 
to maintain healthy phenotype. Additionally, the materials they are manufactured from are often 
neither biodegradable, nor manufactured for direct use and often require enzymatic degradation 
before use [32].  
OBJECTIVE 
The objective of this study is to assess the efficacy of decellularized cartilage 
microcarriers as a cell culture and delivery platform for chondrogenic cells in order to improve 
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current cell therapies used to treat chondral defects. The hypothesis is that decellularized porcine 
articular cartilage microcarriers will support expansion while enhancing the retention of 
chondrogenic phenotype and ECM synthesis in comparison to gelatin microcarriers and standard 
monolayer culture on tissue culture polystyrene. 
MATERIALS & METHODS 
Cartilage Decellularization 
 Fresh porcine cartilage was isolated from the feet of eight market weight pigs 
obtained from a local meat processor. Extraneous tissue was removed to expose the articular 
cartilage surface and care was taken to avoid removing subchondral bone during isolation of the 
articular cartilage. The cartilage pieces were then washed with Dulbecco's phosphate-buffered 
saline, DPBS, and then aspirated before cartilage samples were stored at -80C.   
 Multiple decellularization procedures were compared in order to determine an 
effective method for cellular removal with maximum retention of extracellular matrix 
components, namely glycosaminoglycans, or GAGs. Cartilage pieces were thawed at room 
temperature and washed on a rotary orbital shaker at 250RPM and 37C with 500mL of 
deionized water, 1% Sodium dodecyl sulfate (SDS), or 1% TritonX-100 for 48 hours, or through 
a series of chemical and enzymatic washes based on a protocol used by the Badylak lab shown in 
Table 1 [33].  Samples were fixed in 10% neutral buffered formalin overnight, embedded in 
paraffin, sectioned, and stained with hematoxylin and eosin (H&E) and/or with Safranin-O (Saf 
O) to show lack of visible nuclei and GAG content. In order to determine when GAGs were lost 
during the decellularization, samples were taken after multiple decellularization steps (items 
bolded in Table 1). Shorter trypsin washes (for 1.5 h and 4.5 hours) were also analyzed for GAG 











 Decellularized pieces were incubated with heparin sodium salt and chondroitin 
sulfate in order to determine if GAGs could be reincorporated into decellularized cartilage 
pieces. Chondroitin sulfate, a GAG found in cartilage extracellular matrix, and heparin sodium 
salt, a GAG nonspecific to cartilage, but with a higher negative charge density and therefore 
likely more reactive to binding with the decellularized ECM were added (100, 10, and 1% dry 
weight) to one milligram of decellularized cartilage pieces. The solution was placed in a 
sonicating bath for 15 minutes, incubated for twenty-four hours at 37°C, and washed in DPBS 3 
times for 15 minutes each before staining with Safranin-O and imaging with a dissection scope. 
WASH SOLUTION TIME 
Trypsin 6 h 
Deionized water 15 min, 3x 
70% ethanol 15 h 
3% hydrogen peroxide 15 min 
Deionized water 15 min, twice 
1% Triton X-100 in EDTA/Trizma 6 h 
1% Triton X-100 in EDTA/Trizma 15 h 
Deionized water 15 min 
0.1% PAA/4% ethanol 2 h 
Sterile DPBS 15 min, 3x 
Table 1. Badylak Decellularization Protocol 
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 Due to DNA being found in trypsin from multiple manufacturers, TrypLE 
Express, a purified, recombinant cell-dissociation enzyme was used in place of trypsin. A 
twenty-four hour DNase and RNase wash was also incorporated before the final DPBS wash. All 
decellularization solution was aspirated and decellularized cartilage was frozen at -80°C until 











In order to quantify decellularization, frozen cartilage pieces were subjected to 
lyophilization and digested in proteinase K according to the Quiagen® DNeasy protocol for 
tissues and DNA was quantified with PicoGreen®  reagent and DNA gel electrophoresis. 
Histological samples were also stained with H&E and SafO to show lack of visible nuclei and 
GAG retention respectively. 
Cartilage Microcarrier Formation 
 The decellularized cartilage pieces were lyophilized, flash-frozen in liquid 
nitrogen, and milled with a Thomas Wiley Mini-Mill™ using a 400μm mesh screen. The milled 
cartilage was then sieve sifted overnight to separate microcarriers by size in sieve meshes 
Wash Solution Time 
TrypLE Express 6 h 
Deionized water 15 min, 3x 
70% ethanol  15 h 
3% hydrogen peroxide 15 min 
Deionized water 15 min, twice 
1% Triton X-100 in EDTA/Trizma 6 h 
1% Triton X-100 in EDTA/Trizma 15 h 
Deionized water 15 min, 3x 
14.   DNase/RNase Solution 24 h 
15.   Deionized water 15 min, twice 
16.   Deionized water 15 min 
17.   0.1% PAA/4% ethanol 2 h 
18.   Sterile DPBS 15 min, 3x 
Table 2. Final Decellularization Protocol 
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ranging from 180 μm – 250 μm and 250 μm – 400 μm. The dry weight of cartilage samples after 
each step was recorded in order to determine yield efficiency. After sieving, the microcarriers 
were stained with Eosin for 15 minutes, washed five times with 0.1% TritonX-100 in D-PBS and 
imaged with a confocal microscope (Zeiss 700 LSM). Size was quantified in ImageJ® by 
determining the largest and smallest cross-sectional distances, approximate diameter, and aspect 
ratio of each microcarrier. Commercially available gelatin microcarriers, Cultispher-G were 
also stained and used as a control for comparison. 
Cell Seeding on Microcarriers 
 ATDC5 cells, a mouse teratocarcinoma cell line that mimics mesenchymal 
condensation and chondrogenic differentiation, was used for preliminary cell-loading 
experiments. ATDC5 cells were expanded in ATDC5 growth media consisting of DMEM/F-12 
media with L-glutamine (Invitrogen) supplemented with 5% FBS (Atlanta biologics), 10 μg/mL 
transferrin (Invitrogen), and 3x10-8 M sodium selenite (Sigma-Aldrich) at 3,250 cells/cm2. Cells 
were cultured at 37C in 5% CO2 and fed every 2-3 days until 90% confluent. 
 After trypsinization, ATDC5 cells were seeded at 5x104 cells/cm2  or 5x105 
cells/cm2  on the decellularized cartilage microcarriers through overnight incubation at a high 
cell density (500,000 cells/mL) in ATDC5 growth media in 50 mL conical tubes with 5 mL of 
agarose to provide a flat bottom for microcarriers to settle without clumping. Static, stirred, and 
intermittent stirring conditions were all compared for overnight seeding. After overnight 
incubation, the microcarriers were washed and stained using a Live/Dead viability assay 
(Calcein-AM and Ethidium homodimer-1) and imaged with confocal microscopy to determine 
an optimal seeding method. The media was collected after overnight seeding to determine 
seeding efficiency with a hemocytometer. The microcarriers were then transferred to 6-well 
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suspension plates and cultured on a rotary orbital shaker at 60 RPM for up to 7 days and samples 
were collected at Days 1, 4, and 7 for Live/Dead staining and histological analysis. 
Human Chondrocyte Isolation  
 Human chondrocytes were isolated from the distal end of adult femurs of diabetic 
patients (n=4) undergoing above knee amputations. Briefly, articular cartilage was dissected and 
care was taken to exclude any areas of osteoarthritis. Cartilage was then cut into 2 mm x 2 mm 
pieces and sequentially digested with 1 mg/mL pronase (30 min) and 1mg/mL collagenase type 2 
(overnight) at 37°C with slow agitation. The digested cartilage was then filtered through a 70 μm 
mesh, and any pieces larger than the mesh were resuspended in fresh 1 mg/mL collagenase type 
II and digested for an additional night. Isolated primary chondrocytes were washed in growth 
media consisting of DMEM/F-12, 10% fetal bovine serum, 50µg/mL L-ascorbic acid 2-
phosphate, and penicillin-streptomycin-amphoteracin B (100 U/mL, 100 U/mL, and .25 µg/mL). 
Chondrocytes were frozen in 80% media, 10% FBS, 10% DMSO until microcarrier seeding 
except for a small portion from each donor that were seeded immediately on TCPS for endotoxin 
testing with the HEK-Blue LPS Detection Kit. Any vials from donors that tested positive for 
endotoxin were immediately disposed of (1 donor/4 donors total for a final n=3). Monolayer 
cultures on tissue culture treated polystyrene (TCPS) were used as a control for comparison with 
microcarrier culture and cells were seeded at 1x104 cells/cm2 in growth media and media changes 
were performed every 2-3 days. At day 7, one TCPS chondrocyte plate was passaged to result in 
TCPS P1 and P2 groups on day 14.   
 
Figure 1. Primary Human Chondrocyte Isolation. Human chondrocytes isolated from the femurs (A) of diabetic 
patients were isolated (B) after digest in pronase and collagenase over 2 nights (B). 
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Chondrocyte expansion on microcarriers  
 The decellularized cartilage (180-250 micron sieve) and Cultispher-G microcarriers 
were rehydrated in chondrocyte growth media for 30 minutes before cell loading. Primary human 
chondrocytes pooled from 3 donors were then seeded at 1x104 cells/cm2, mixed with gentle 
pipetting with a wide-bore pipette, and then split in 12-well Nunclon Sphera suspension plates. 
The monolayer and suspension microcarrier culture plates were placed in the same incubator at 
37C and 5% CO2. The microcarrier cell suspension was incubated under static conditions at 
250,000 cells/mL overnight, after which time the microcarriers were again mixed with gentle 
pipetting, allowed to settle, and then media was taken off to assess seeding efficiency. The 
microcarriers were supplemented with 1 mL/well of chondrocyte growth media and placed on a 
rotary orbital shaker at 80 RPM for the duration of the experiment. Media changes were 
performed every 2-3 days and samples were collected at days 1, 7, and 14 in order to assess 
viability, proliferation, and ECM deposition. Histological samples were fixed in 10% neutral 
buffered formalin, manually processed for histology, and embedded in paraffin. Samples were 
then sectioned (5µm) for routine histology with hematoxylin and eosin (H&E) and safranin 
O/fast green (Saf O) staining. Samples collected for GAG deposition were washed in DPBS and 
then collected in lysis buffer (Quiagen), and frozen. At the conclusion of the experiment samples 
were digested with 20 μL Proteinase K overnight at 60°C for GAG quantification with a 
dimethyl-methylene blue (DMMB) assay and DNA quantification with PicoGreen® . 
Statistical Analysis 
 Quantitative data was compared using GraphPad® Prism 5.0 for statistical significance 
using analysis of variance (ANOVA) with multiple comparisons and Bonferroni's correction 
(α=0.05) wherever appropriate. Otherwise Student's t-tests were performed with α=0.05 also 




 Histological comparisons of multiple decellularization protocols revealed only complete 
nuclei removal with a multi-step multi-wash protocol and 48 hours in deionized water, 1% SDS, 
or 1% Triton X-100 all yielded insufficient cellular removal (Figure 2). Although the Badylak 
decellularization did remove nuclei, Safranin-O staining also revealed GAG depletion after this 
process (Figure 3).Analysis of GAG retention after each decellularization step revealed GAG 
removal during the initial trypsin wash (Figure 4A) and shorter durations in trypsin still resulted 
in GAG depletion (Figure 4B). Removing trypsin wash completely from the protocol resulted in 
incomplete cell removal with visible nuclei present after the final wash (Figure 4C).  
 Efforts to redeposit glycosaminoglycans on decellularized cartilage microcarrier surfaces 
through charge interactions via overnight incubation were largely unsuccessful. There was a 
large amount of variability in the heparin sulfate incubated microcarriers with some positive 
staining in all groups and less variability in the microcarrier group with the highest concentration 
(100% weight matched) of heparin sulfate. There was no positive staining in the chondroitin 
sulfate incubated samples (Figure 5). 
 Because the protease wash of the protocol was responsible for both effective 
decellularization and glycosaminoglycan depletion in the cartilage sample, the final 
decellularization protocol was modified to include a TrypLE wash and DNase/RNase wash 
(Table 2). Effective decellularization was evidenced by the lack of visible nuclei in both H&E 
and Hoechst staining (Figure 6 A&B) and the absence of DNA band on gel electrophoresis 
(Figure 6 C). DNA quantification confirmed that the decellularized cartilage microcarriers 
contained less than 2% of original DNA content of the native cartilage (Figure 6 D). 
Decellularization also removed the majority of glycosaminoglycans, as evidenced by lack of 




Figure 2. Histological comparison of various decellularization protocols on porcine articular cartilage. 
Hematoxylin and eosin (H&E) staining was performed on porcine cartilage pieces and microcarriers undergoing 
different decellularization protocols. Nuclei were stained dark brown and positive nuclei staining was visible 
following 48 hour washes in water, 1% SDS, or 1% TritonX-100 while no nuclei were present in microcarriers or 
pieces after the more complex Badylak decellularization protocol. 
 
 
Figure 3. GAG depletion in decellularized porcine articular cartilage pieces. Porcine cartilage pieces and milled 
microcarriers were stained with Safranin-O before and after decellularization to assess glycosaminoglycan content. 
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Figure 4. Comparison of glycosaminoglycan retention with various decellularization procedures with 
Safranin-O staining. Samples taken at multiple time points during Badylak decellularization indicate 
glycosaminoglycan loss after first trypsin wash (A). Shorter trypsin washes still resulted in glycosaminoglycan 
depletion (B) and decellularization procedures omitting trypsin resulted in inefficient decellularization with visible 
nuclei after the final PAA wash although glycosaminoglycans were largely retained (C). 
 
 
Figure 5. Assessing the deposition of glycosaminoglycans on cartilage microcarriers following 
decellularization. Safranin-O staining of decellularized cartilage samples incubated with heparin sulfate resulted in 
some positive staining for glycosaminoglycans with more positive staining at the highest concentration, but there 
was a large amount of sample variability in within all of the tested concentrations. Safranin-O staining on samples 
incubated with chondroitin sulfate resulted in no positive staining at any concentration. 
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Figure 6. Characterization of decellularized cartilage microcarriers. Decellularization of porcine cartilage 
microcarriers was verified via lack of visible nuclei after hematoxylin & eosin (H&E) (A) & Hoechst staining (B), 
lack of visible DNA after gel electrophoresis (C), and 99% DNA removal quantified via PicoGreen® assay (D) (*t-
test p<0.05 vs native cartilage). Safranin-O staining shows decellularization also removes glycosaminoglycans (E).  
 
Microcarrier characterization 
 Microcarrier yield was determined by quantifying the initial mass of the cartilage pieces, 
the mass after decellularization, and the mass of the carriers of each size range after sieving 
(Figure 7). The majority of microcarrier loss occurred during decellularization, though sample 
was lost during milling and sieving steps as well (Figure 7A). Size analysis was performed on 
DC and CG microcarriers using microscopy and image analysis (Figure 7 B-D). Hydrated CG 
carriers had a diameter around 250 μm while the 180-250 sieved DC microcarriers were around 
400 μm as determined by confocal microscopy and image analysis with Image J (Figure 7 B). 
The CG carriers were more spherical with an aspect ratio around 1.2 while DC microcarrier 
aspect ratio was around 1.5 (Figure 7 C&D). 
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Figure 7. Microcarrier yield and size characterization. The final yield of the 180-250 and 250-400 micron sieved 
microcarriers was 15% and 16% of the initial weight of the cartilage pieces respectively and the majority of loss 
during processing was due to decellularization (A). The 180-250 micron sieved DC µCs were larger in comparison 
to commercially available CG µCs with hydrated diameters around 400 and 250 microns respectively based on 
ImageJ® analysis of the longest side, shortest side, and average diameters across µCs (n=105 and 97, respectively) 
@p<0.05 vs DC µCs ANOVA with Bonferroni correction (B). DC µCs and CG µCs both varied in size with some 
clumping even in the absence of cells (C). The CG µCs were more round than the DC µCs, resulting in an aspect 





ATDC5 Expansion on Microcarriers 
 
 In order to compare cell seeding protocols and loading efficiency on microcarriers, 
ATDC5 cells, a chondrogenic mouse teratocarcinoma cell line, were used for initial seeding 
studies. The size analyses were used to approximate microcarrier diameter and subsequent 
surface area in order to seed the DC and CG microcarriers at 5x104 or 5x105 cells/cm2. The 
ATDC5 cells proliferated over the 7-day culture period and maintained a high viability (Figure 8 
A&B). As expected, the cells did not infiltrate the microcarriers over this period and proliferated 
primarily on the surface/edges of the decellularized microcarriers as seen by positive nuclei 
staining with hematoxylin and eosin (Figure 8 C). Overall, there was little difference in the 
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seeding efficiency, viability, and expansion of ATDC5 cells on the microcarriers of different 
sizes, but most commonly used commercially available microcarriers are similar in size to the 
smaller microcarriers, thus only the 180-250 µm sieved microcarriers were chosen for further 
analysis with human chondrocyte culture. 
 
Figure 8. Chondrogenic ATDC5 cells attach to and proliferate on decellularized cartilage microcarriers and 
maintain a high viability over 7 days of culture. The chondrogenic mouse teratocarcinoma ATDC5 cell line 
maintained a high viability and proliferated up to 7 days on both 180- 250 micron sieved µCs (A) and 250-400 
micron sieved µCs (B). The cells proliferated on the surfaces/edges of the decellularized microcarriers, as seen by 
positive nuclei staining with hematoxylin along the borders of the sectioned µCs for both sizes (C). 
 
Primary Human Chondrocyte Expansion on Microcarriers 
 
 The primary chondrocytes proliferated on all surfaces (DC µCs, CG µCs, and TCPS) 
over the 14-day culture period and maintained a high viability as represented by live/dead 
confocal imaging (Figure 9). PicoGreen® DNA analysis indicated better attachment to the DC 
microcarriers than the CG microcarriers or TCPS based on Day 1 DNA content (Figure 10 A). 
The cells proliferated on all three of the surfaces with significant increases on day 7 and day 14 
from the previous time points (Figure 10 A). The Day 14 P2 samples that were passaged at day 7 
were very similar in DNA content to the Day 7 P1 samples, indicating that the chondrocytes 
maintain their proliferative capacity in the second passage (Figure 10 A). Decellularized 
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cartilage and Cultispher-G microcarriers both had a significantly higher amount of DNA than 
tissue culture polystyrene expanded groups on days 7 and 14 (Figure 10 A). Chondrocytes 
cultured on tissue culture polystyrene without passaging had significantly higher DNA content 
on day 14 than chondrocytes on their second passage (Figure 10 A). Dimethyl-methylene blue 
(DMMB) assay showed glycosaminoglycan content had no significant differences across time 
points for chondrocyte laden decellularized cartilage microcarriers other than in comparison to 
unloaded carriers (Figure 10 B). CG microcarriers and TCPS chondrocytes had significantly less 
GAG content than DC microcarriers at all timepoints or as unloaded microcarriers (Figure 11 B). 
GAG content increased on day 14 for both chondrocytes cultured on CG microcarriers and TCPS 
in comparison to days 1 and 7 (Figure 10 B). Day 14 passage 2 cells had less GAG content than 
day 14 passage 1 samples (Figure 10 B). The DC microcarrier cultured chondrocytes were the 
only group that had a significant increase in GAG content after just 1 day in comparison to the 
unloaded control DC microcarriers. When GAG content was normalized to DNA, the DC 
microcarrier group had significantly more GAG/DNA in comparison to native cartilage on day 1, 
but that ratio decreased at each time point as the number of cells increased with levels most 
similar to native cartilage occurring after 7 days of culture (Figure 10 C). The GAG/DNA 
content was higher in DC microcarrier groups at all time points than the CG microcarrier or 
TCPS groups (Figure 10 C). There was no significant difference in normalized GAG content 
over any time point for the CG microcarrier and TCPS groups (Figure 10 C).    
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Figure 9. Primary human chondrocytes attach to and proliferate on ECM microcarriers over 14 days while 
maintaining high viability. Primary human chondocytes seeded on decellularized cartilage microcarriers (DC 
Microcarriers), Cultispher-G Microcarriers (CG Microcarriers), and  tissue culture polystyrene (TCPS) at 5x104 
cells/cm2 maintained a high viability and proliferated up to 14 days as evidenced by confocal images after 





Figure 10. Primary human chondrocytes proliferate on ECM microcarriers faster than TCPS and DC µC 
culture maintains higher GAG/DNA content than CG µCs or TCPS. DNA was quantified with PicoGreen® 
Assay for unloaded and chondrocyte-loaded microcarriers and TCPS cultured chondrocytes over 14 days (A). GAG 
content was quantified with dimethyl-methylene blue assay (B) and normalized to DNA and compared to native 
cartilage (C). p<0.05 ANOVA with multiple comparisons * vs unloaded microcarriers from same group (A & B) or 
native cartilage (C), $ vs Day 1 same group, # vs day 7 same group, % vs day 14  P1 same group, @ vs DC same 




 This study aimed to develop a novel cartilage ECM-derived microcarrier platform to 
promote the retention of the chondrogenic phenotype and reduce chondrocyte dedifferentiation 
during in vitro expansion. Previous studies have separately focused on the expansion of 
chondrocytes on microcarriers or decellularized tissue, but both have had drawbacks. Current 
microcarrier platforms do not provide the rich environment of bioactive factors the native 
cartilage ECM is composed of, and decellularized cartilage sheets failed when implanted in vivo 
due to their limited integration with chondral defects and low cellularity [14, 27, 29, 30]. The 
aim of this study was to combine microcarrier expansion and decellularized cartilage tissue to 
create a novel microcarrier platform that would promote chondrogenic expansion and act as a 
biocompatible delivery vessel as a solution to the current drawbacks of cell-based therapies used 
to treat chondral defects.   
 Decellularization of porcine articular cartilage was achieved through modification of a 
previous protocol [33]. The successful removal of cellular contents was associated with the 
reduction of glycosaminoglycans, molecules which add to the osmotic properties and therefore 
mechanical load distribution of cartilage ECM [1]. Attempts to redeposit glycosaminoglycans on 
the surface of decellularized microcarriers through simple incubations were unsuccessful. While 
decellularization removed most of the native GAGs, the DC microcarriers retained some GAGs 
and had similar proportions of GAG to DNA as native articular cartilage after 7 days of 
chondrocyte culture, which was significantly better than expansion on CG microcarriers or tissue 
culture polystyrene. Interestingly, the chondrocytes were unable to produce enough GAG to 
retain the same GAG/DNA ratio over 14 days. One hypothesis for this is that secreted GAGs 
could have been released into the media rather than becoming incorporated into the 
decellularized ECM. GAG deposition in media has previously been quantified in plated primary 
human chondrocytes over-expressing SOX9 and IGF-I in conditioned media rather than cell 
sample digests, suggesting that chondrocyte synthesis of GAGs might be present in conditioned 
media in addition to cell scaffolds [34].  Conditioned media collected from our samples will be 
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used for a DMMB analysis and total GAG (secreted and cell/ECM-bound) will be compared 
between each group in addition to the cell/ECM bound digests we have already analyzed.   
 The underlying collagen network provides a structure for GAG incorporation and 
attachment, and therefore further analysis of the collagen structure may lend an explanation to 
this lack of increase in GAG deposition [35]. While the relatively high GAG/DNA ratio of DC 
microcarrier cultured chondrocytes is encouraging, the ratio of collagen type II to collagen type I 
is the most common method of analyzing dedifferentiation [34]. Ongoing studies will analyze the 
col II/col I ratio by quantifying RNA of the cultured chondrocytes with Fluidigm. Samples were 
already collected and other chondrogenic (Sox9, aggrecan, cartilage oligomeric matrix protein), 
and hypertrophic (collagen type X) markers will be assessed and normalized to housekeeping 
genes (GAPDH and RPS-18) [36]. Immunohistochemical staining of Collagens I, II, and X will 
also be used to validate these findings.    
 
CONCLUSION 
 Cell based therapies used to treat osteoarthritis are currently handicapped by the inability 
to expand chondrocytes ex vivo without loss of phenotype and resulting dedifferentiation. A cell 
culture platform that will successfully stimulate proliferation and chondrogenesis over lengthy 
expansions ex vivo is required in order to allow for the advancement of cell based therapies 
aimed at treating degenerative joint diseases such as osteoarthritis. By utilizing decellularized 
articular cartilage tissue, this study has better captured the biological microenvironment 
chondrocytes are exposed to in native cartilage ECM, enhancing the potential for retention of a 
chondrogenic phenotype. The utilization of a microcarrier platform may better allow for not only 
cellular expansion, but also improved tissue integration and more rapid regeneration with the use 
of this combinatorial delivery chondrocyte and ECM to cartilage defects in vivo. In order to 
confirm the hypothesis that decellularized porcine articular cartilage microcarriers will support 
expansion while enhancing the retention of a chondrogenic phenotype and ECM synthesis in 
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comparison to gelatin microcarriers and standard monolayer culture on tissue culture 
polystyrene, the Col II/Col I ratio must be quantified and analyzed for all aforementioned groups. 
  In conclusion, this study has shown the potential for a novel decellularized cartilage 
derived substrate that could serve as both a cell expansion platform, as well as a cell delivery 
method in future cell based therapies for degenerative joint diseases.  
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